U.S. Army Reports Progress on COVID-19 Vaccine That Fights All Variants

0
62


(HealthDay News) — The U.S. Army says it has developed a COVID-19 vaccine it believes could work against any and all coronavirus variants, including omicron. Results from early human trials of the Spike Ferritin Nanoparticle (SpFN) COVID-19 vaccine are expected by the end of the month, the Army added.

Lab studies have already shown that the new vaccine protects monkeys from the original strain of COVID-19, and induces highly potent antibody responses against the major variants of concern that have emerged during the pandemic, claims a report published last week in the journal Science Translational Medicine. The upcoming results from phase I human trials, which started in April 2021 and aimed to include a total of 72 people, will show whether the effectiveness observed in monkeys carried over into humans, the researchers said.

“Our strategy has been to develop a ‘pan-coronavirus’ vaccine technology that could potentially offer safe, effective, and durable protection against multiple coronavirus strains and species,” Kayvon Modjarrad, M.D., co-inventor of the vaccine and director of the Emerging Infectious Diseases Branch at the Walter Reed Army Institute of Research, said in an Army news release.


Continue Reading

The SpFN vaccine uses a protein shaped like a soccer ball, according to an article on the national security news site Defense One. Each of the molecule’s 24 different faces could carry a different spike protein drawn from unique COVID-19 variants, creating a broad immune response against the coronavirus, Defense One reports.

“This vaccine stands out in the COVID-19 vaccine landscape,” Modjarrad said. “The repetitive and ordered display of the coronavirus spike protein on a multifaced nanoparticle may stimulate immunity in such a way as to translate into significantly broader protection.”

More Information



Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here